Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.
One of the major factors responsible for the market's growth is the increasing interests of several vendors on the development of novel drugs to gain a competitive advantage over their competitors. For instance, Bayer HealthCare launched Zelnate in the US, which is a bacterial-produced plasmid DNA including a liposome carrier that helps to stimulate the innate immune system in cattle. Furthermore, under traditional antibiotics segment also, vendors are launching various drugs such as draxxin for the cattle respiratory disease treatment. The growing focus on the development of combination drugs will drive the growth prospects for the global BRD treatment market for the next few years. Some of the major factors responsible for the growing number of development of combination drugs is the need to offer improved efficacy and ensure better treatment outcomes.
This report provides a complete quantitative data and qualitative analysis on the global market for Bovine Respiratory Disease Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Bovine Respiratory Disease Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Bovine Respiratory Disease Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Bovine Respiratory Disease Treatment, including the following market information:
Global Bovine Respiratory Disease Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Bayer HealthCare, Boehringer Ingelheim, Elanco, Merck, Zoetis, Ceva, Inovio Pharmaceuticals, Norbrook Laboratories, Plumbline Life Sciences, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Vaccines
Antibiotics
Immunomodulators
Others
Based on the Application:
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Private Veterinary Pharmacies
One of the major factors responsible for the market's growth is the increasing interests of several vendors on the development of novel drugs to gain a competitive advantage over their competitors. For instance, Bayer HealthCare launched Zelnate in the US, which is a bacterial-produced plasmid DNA including a liposome carrier that helps to stimulate the innate immune system in cattle. Furthermore, under traditional antibiotics segment also, vendors are launching various drugs such as draxxin for the cattle respiratory disease treatment. The growing focus on the development of combination drugs will drive the growth prospects for the global BRD treatment market for the next few years. Some of the major factors responsible for the growing number of development of combination drugs is the need to offer improved efficacy and ensure better treatment outcomes.
This report provides a complete quantitative data and qualitative analysis on the global market for Bovine Respiratory Disease Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Bovine Respiratory Disease Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Bovine Respiratory Disease Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Bovine Respiratory Disease Treatment, including the following market information:
Global Bovine Respiratory Disease Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bovine Respiratory Disease Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Bayer HealthCare, Boehringer Ingelheim, Elanco, Merck, Zoetis, Ceva, Inovio Pharmaceuticals, Norbrook Laboratories, Plumbline Life Sciences, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Vaccines
Antibiotics
Immunomodulators
Others
Based on the Application:
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Private Veterinary Pharmacies
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Bovine Respiratory Disease Treatment Industry
1.7 COVID-19 Impact: Bovine Respiratory Disease Treatment Market Trends
2 Global Bovine Respiratory Disease Treatment Quarterly Market Size Analysis
2.1 Bovine Respiratory Disease Treatment Business Impact Assessment - COVID-19
2.1.1 Global Bovine Respiratory Disease Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Bovine Respiratory Disease Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Bovine Respiratory Disease Treatment Quarterly Market Size, 2019 VS 2020
3.2 By Players, Bovine Respiratory Disease Treatment Headquarters and Area Served
3.3 Date of Key Players Enter into Bovine Respiratory Disease Treatment Market
3.4 Key Players Bovine Respiratory Disease Treatment Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Bovine Respiratory Disease Treatment Segments, By Type
4.1 Introduction
1.4.1 Vaccines
1.4.2 Antibiotics
1.4.3 Immunomodulators
1.4.4 Others
4.2 By Type, Global Bovine Respiratory Disease Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Bovine Respiratory Disease Treatment Segments, By Application
5.1 Overview
5.5.1 Veterinary Clinics
5.5.2 Veterinary Hospitals
5.5.3 Veterinary Research Institutes
5.5.4 Private Veterinary Pharmacies
5.2 By Application, Global Bovine Respiratory Disease Treatment Market Size, 2019-2021
5.2.1 By Application, Global Bovine Respiratory Disease Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Bayer HealthCare
7.1.1 Bayer HealthCare Business Overview
7.1.2 Bayer HealthCare Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.1.3 Bayer HealthCare Bovine Respiratory Disease Treatment Product Introduction
7.1.4 Bayer HealthCare Response to COVID-19 and Related Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Business Overview
7.2.2 Boehringer Ingelheim Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.2.3 Boehringer Ingelheim Bovine Respiratory Disease Treatment Product Introduction
7.2.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.3 Elanco
7.3.1 Elanco Business Overview
7.3.2 Elanco Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.3.3 Elanco Bovine Respiratory Disease Treatment Product Introduction
7.3.4 Elanco Response to COVID-19 and Related Developments
7.4 Merck
7.4.1 Merck Business Overview
7.4.2 Merck Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.4.3 Merck Bovine Respiratory Disease Treatment Product Introduction
7.4.4 Merck Response to COVID-19 and Related Developments
7.5 Zoetis
7.5.1 Zoetis Business Overview
7.5.2 Zoetis Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.5.3 Zoetis Bovine Respiratory Disease Treatment Product Introduction
7.5.4 Zoetis Response to COVID-19 and Related Developments
7.6 Ceva
7.6.1 Ceva Business Overview
7.6.2 Ceva Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.6.3 Ceva Bovine Respiratory Disease Treatment Product Introduction
7.6.4 Ceva Response to COVID-19 and Related Developments
7.7 Inovio Pharmaceuticals
7.7.1 Inovio Pharmaceuticals Business Overview
7.7.2 Inovio Pharmaceuticals Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.7.3 Inovio Pharmaceuticals Bovine Respiratory Disease Treatment Product Introduction
7.7.4 Inovio Pharmaceuticals Response to COVID-19 and Related Developments
7.8 Norbrook Laboratories
7.8.1 Norbrook Laboratories Business Overview
7.8.2 Norbrook Laboratories Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.8.3 Norbrook Laboratories Bovine Respiratory Disease Treatment Product Introduction
7.8.4 Norbrook Laboratories Response to COVID-19 and Related Developments
7.9 Plumbline Life Sciences
7.9.1 Plumbline Life Sciences Business Overview
7.9.2 Plumbline Life Sciences Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.9.3 Plumbline Life Sciences Bovine Respiratory Disease Treatment Product Introduction
7.9.4 Plumbline Life Sciences Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Bovine Respiratory Disease Treatment Industry
1.7 COVID-19 Impact: Bovine Respiratory Disease Treatment Market Trends
2 Global Bovine Respiratory Disease Treatment Quarterly Market Size Analysis
2.1 Bovine Respiratory Disease Treatment Business Impact Assessment - COVID-19
2.1.1 Global Bovine Respiratory Disease Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Bovine Respiratory Disease Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Bovine Respiratory Disease Treatment Quarterly Market Size, 2019 VS 2020
3.2 By Players, Bovine Respiratory Disease Treatment Headquarters and Area Served
3.3 Date of Key Players Enter into Bovine Respiratory Disease Treatment Market
3.4 Key Players Bovine Respiratory Disease Treatment Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Bovine Respiratory Disease Treatment Segments, By Type
4.1 Introduction
1.4.1 Vaccines
1.4.2 Antibiotics
1.4.3 Immunomodulators
1.4.4 Others
4.2 By Type, Global Bovine Respiratory Disease Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Bovine Respiratory Disease Treatment Segments, By Application
5.1 Overview
5.5.1 Veterinary Clinics
5.5.2 Veterinary Hospitals
5.5.3 Veterinary Research Institutes
5.5.4 Private Veterinary Pharmacies
5.2 By Application, Global Bovine Respiratory Disease Treatment Market Size, 2019-2021
5.2.1 By Application, Global Bovine Respiratory Disease Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Bayer HealthCare
7.1.1 Bayer HealthCare Business Overview
7.1.2 Bayer HealthCare Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.1.3 Bayer HealthCare Bovine Respiratory Disease Treatment Product Introduction
7.1.4 Bayer HealthCare Response to COVID-19 and Related Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Business Overview
7.2.2 Boehringer Ingelheim Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.2.3 Boehringer Ingelheim Bovine Respiratory Disease Treatment Product Introduction
7.2.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.3 Elanco
7.3.1 Elanco Business Overview
7.3.2 Elanco Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.3.3 Elanco Bovine Respiratory Disease Treatment Product Introduction
7.3.4 Elanco Response to COVID-19 and Related Developments
7.4 Merck
7.4.1 Merck Business Overview
7.4.2 Merck Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.4.3 Merck Bovine Respiratory Disease Treatment Product Introduction
7.4.4 Merck Response to COVID-19 and Related Developments
7.5 Zoetis
7.5.1 Zoetis Business Overview
7.5.2 Zoetis Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.5.3 Zoetis Bovine Respiratory Disease Treatment Product Introduction
7.5.4 Zoetis Response to COVID-19 and Related Developments
7.6 Ceva
7.6.1 Ceva Business Overview
7.6.2 Ceva Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.6.3 Ceva Bovine Respiratory Disease Treatment Product Introduction
7.6.4 Ceva Response to COVID-19 and Related Developments
7.7 Inovio Pharmaceuticals
7.7.1 Inovio Pharmaceuticals Business Overview
7.7.2 Inovio Pharmaceuticals Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.7.3 Inovio Pharmaceuticals Bovine Respiratory Disease Treatment Product Introduction
7.7.4 Inovio Pharmaceuticals Response to COVID-19 and Related Developments
7.8 Norbrook Laboratories
7.8.1 Norbrook Laboratories Business Overview
7.8.2 Norbrook Laboratories Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.8.3 Norbrook Laboratories Bovine Respiratory Disease Treatment Product Introduction
7.8.4 Norbrook Laboratories Response to COVID-19 and Related Developments
7.9 Plumbline Life Sciences
7.9.1 Plumbline Life Sciences Business Overview
7.9.2 Plumbline Life Sciences Bovine Respiratory Disease Treatment Quarterly Revenue, 2020
7.9.3 Plumbline Life Sciences Bovine Respiratory Disease Treatment Product Introduction
7.9.4 Plumbline Life Sciences Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
